Results 171 to 180 of about 9,899,312 (276)

Tumour‐proximal deep serum proteomics identifies biomarkers associated with ovarian cancer

Molecular Oncology, EarlyView.
New biomarkers are needed for early ovarian cancer detection. Ovarian (tumour‐proximal) and peripheral vein serum from healthy women and patients with benign or malignant tumours underwent nanoparticle‐enriched deep proteomics. Ovarian serum yielded more protein identifications and revealed tumour‐reflective signatures.
Darren Lau, Daniel Pincher, Clifford Young, Nicholas Chappell, Noor A. Lokman, Parul Mittal, Leigh Donnellan, Martin K. Oehler, Doug A. Brooks, Peter Hoffmann   +9 more
wiley   +1 more source

Sample Size Calculation in Dose Optimization Trials Using the Margin of Practical Non-Inferiority. [PDF]

Stat Med
Dehbi HM, Devlins S, Iasonos A, Nankivell M, Gilbert D, O'Quigley J.   +5 more
europepmc   +1 more source

Attitudes of cancer patients toward ctDNA‐based liquid biopsy for follow‐up

Molecular Oncology, EarlyView.
This mixed‐methods study explored cancer patients' experiences, knowledge, and preferences regarding ctDNA‐based liquid biopsy for follow‐up. Awareness of ctDNA was low and recall of previous liquid biopsy was imperfect, yet acceptance was high.
Siddharth Chhajlani, Laura Mariën, Caro De Weerdt, Sanne Wouters, Laure‐Anne Teuwen, Hans Prenen, Katleen Janssens, Timon Vandamme   +7 more
wiley   +1 more source

Power and Sample Size Calculation for Multivariate Longitudinal Trials Using the Longitudinal Rank Sum Test. [PDF]

Stat Med
Ghosh D, Xu X, Luo S, CPP Integrated Parkinson's Database.   +3 more
europepmc   +1 more source

The impact of leukocyte‐associated RNA retention on platelet RNA‐based cancer detection

Molecular Oncology, EarlyView.
Platelets carry RNA signals that may help detect cancer, but platelet samples can also retain RNA from white blood cells. We found that this retained white blood cell signal did not significantly affect machine learning cancer classification, suggesting that the cancer‐related RNA signal in platelets is largely independent of leukocyte‐associated RNA ...
Michał Sieczczyński, Krzysztof Pastuszak, Anna Samelak‐Czajka, Zuzanna Cemka, Paulina Jackowiak, Tomasz Stefaniak, Sylwia Łapińska‐Szumczyk, Jacek Jassem, Anna J. Żaczek, Matthew T. Rondina, Myron G. Best, Sjors G. J. G. In 't Veld, Anna Supernat   +12 more
wiley   +1 more source

A Systematic Review on Power Estimation and Sample Size Calculation in Randomized Controlled Trials of Surgical Treatments for Benign Prostatic Hyperplasia. [PDF]

Cureus
Akintelure D, Agada RU, Akintelure S, Wijayasuriya DS, Abolanle P.   +4 more
europepmc   +1 more source

Sample-size calculation for preclinical dose-response experiments using heterogeneous tumour models. [PDF]

Radiother Oncol, 2021
Ciecior W, Ebert N, Borgeaud N, Thames HD, Baumann M, Krause M, Löck S.   +6 more
europepmc   +1 more source

Overcoming platinum resistance by the disulfiram metabolite CuET in novel preclinical models of human carcinomas

Molecular Oncology, EarlyView.
Cisplatin‐resistant cancer cells survive DNA‐damaging platinum‐based treatment yet remain sensitive to CuET‐induced proteotoxic stress. The distinct mechanism of action allows CuET to overcome and eliminate cisplatin‐resistant tumour cells, unless highly expressed metallothioneins (MTs) interfere with CuET, thereby highlighting MT levels as candidate ...
Stefanos Arampatzis, Tereza Buchtová, Jirina Bartkova, Marie Lund Bay, Christoffer Lynge Halvorsen, Zuzana Machacova, Zdenek Skrott, Martin Mistrik, Ekaterina Dulina, Miguel Andujar‐Sanchez, Estrid Høgdall, Tine Henrichsen Schnack, Claus Høgdall, Berit Jul Mosgaard, Marie Boennelycke, Jacob Brink Laursen, Allan Jensen, Susanne K. Kjær, Tuula Kallunki, Robert Strauss, Jiri Bartek   +20 more
wiley   +1 more source

Pitfalls in Reporting Sample Size Calculation Across Randomized Controlled Trials Involving Ivermectin for the treatment of COVID-19. [PDF]

Am J Ther, 2021
Kow CS, Hasan SS.
europepmc   +1 more source

An outer membrane vesicle‐associated two‐track model for enterotoxigenic Bacteroides fragilis oncogenesis

Molecular Oncology, EarlyView.
Enterotoxigenic Bacteroides fragilis is a gut bacterium linked to bowel cancer. We propose that its toxin acts along two routes: at the cell surface, cutting the adhesion protein E‐cadherin and triggering inflammation; and inside the cell, delivered by bacterial vesicles, switching on NOD1 and cancer stem cell programs.
Kangchan Choi, Sang‐Hyeon Yoo, Ki‐Jong Rhee   +2 more
wiley   +1 more source